Keros Therapeutics, Inc. ( KROS ) Reports Q2 Loss, Beats Revenue Estimates
Keros Therapeutics (KROS) delivered earnings and revenue surprises of +33.33% and +135.95%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Keros to Exclusively Prioritize the Clinical Advancement of KER-065 - Keros Therapeutics ( NASDAQ:KROS )
Company Discontinuing Development of Cibotercept ( KER-012 ) Announces Board and Leadership Changes Designed to Support Streamlined Operational Structure and Strategic Realignment
KROS vs. EXAS: Which Stock Should Value Investors Buy Now?
KROS vs. EXAS: Which Stock Is the Better Value Option?
Will Reblozyl Enable BMY to Offset the Impact of Generic Competition?
Reblozyl sales surged 35% in Q1 for BMY, but a failed phase III study clouds expansion plans amid stiff anemia drug competition.
RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure
Rocket Pharmaceuticals jumps 16.8% as FDA grants RMAT status to RP-A601 on positive phase I heart disease data.
FDA Advisory Panel Votes Against Approval of GSK's Blenrep Combo
GSK stock falls as an FDA panel votes against its Blenrep combo, casting doubt on U.S. approval hopes.
KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock Up
Krystal Biotech climbs after dosing begins in a phase I/II trial for KB801, a gene therapy eye drop targeting neurotrophic keratitis.
RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data
Rhythm Pharmaceuticals jumps 36.6% after its oral drug bivamelagon shows strong BMI and hunger reductions in a phase II study in acquired hypothalamic obesity.
Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst - Keros Therapeutics ( NASDAQ:KROS )
Analyst cuts Keros rating to Neutral, citing limited near-term catalysts and cautious investor sentiment. $375M capital return announced, but unclear structure and delayed KER-065 updates weigh on stock outlook. Get the Strategy to Trade Pre-Fed Setups and Post-Fed Swings-Live With Chris Capre ...
Keros Announces Return of $375 Million in Excess Capital to Stockholders
Concludes Strategic Alternatives Review and Provides Update on Development of KER-065 Concludes Strategic Alternatives Review and Provides Update on Development of ...
Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference - Keros Therapeutics ( NASDAQ:KROS )
LEXINGTON, Mass., June 06, 2025 ( GLOBE NEWSWIRE ) -- Keros Therapeutics, Inc. ( "Keros" ) KROS, a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of ...
Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference
LEXINGTON, Mass., June 06, 2025 ( GLOBE NEWSWIRE ) -- Keros Therapeutics, Inc. ( "Keros" ) ( Nasdaq: KROS ) , a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional ...
Keros Therapeutics Stops PAH Drug Development, Shrinks Workforce By 45% - Keros Therapeutics ( NASDAQ:KROS )
Keros will cut 45% of its workforce, leaving 85 employees and saving about $17 million annually. No improvement in PVR or 6MWD was seen; higher pericardial effusions in cibotercept arms vs. placebo. Get stock picks, daily rankings, and pro-level trading tools in one powerful platform-Memorial ...
Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring
Discontinues Development of Cibotercept in PAH ...
Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring - Keros Therapeutics ( NASDAQ:KROS )
Discontinues Development of Cibotercept in PAH Announces Corporate Restructuring to Align Operations with Ongoing Strategic Priorities
Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote "FOR" All of Keros' Director Nominees
Keros Board Best Equipped to Oversee Strategic Review Process and Execute on Ultimate Outcome of that Process ...
Keros Therapeutics Highlights Commitment to Maximizing Stockholder Value - Keros Therapeutics ( NASDAQ:KROS ) , Takeda Pharmaceutical Co ( NYSE:TAK )
Files Investor Presentation and Issues Open Letter to Stockholders Urges Stockholders to Protect the Value of Their Investment by Voting "FOR" Each of the Company's Highly Qualified Director Nominees
ADAR1 Capital Management Releases Investor Presentation Outlining Its Rationale for Withholding Votes From Directors Dr. Mary Ann Gray and Dr. Alpna Seth - Keros Therapeutics ( NASDAQ:KROS )
AUSTIN, Texas, May 12, 2025 /PRNewswire/ -- ADAR1 Capital Management, LLC ( together with its affiliates, "ADAR1" ) , the largest stockholder of Keros Therapeutics KROS ( "Keros" or the "Company" ) with approximately 13.3% of the Company's outstanding shares, today released an investor ...
Keros Reinforces Commitment to Maximizing Stockholder Value
Responds to Recent Public Stockholder Communications ...
ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders - Keros Therapeutics ( NASDAQ:KROS )
Announces Intention to Withhold Votes for Directors Dr. Mary Ann Gray and Dr. Alpna Seth
Keros Therapeutics, Inc. ( KROS ) Q1 Earnings and Revenues Beat Estimates
Keros Therapeutics (KROS) delivered earnings and revenue surprises of 36,300% and 149.64%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Syndax Pharmaceuticals ( SNDX ) Reports Q1 Loss, Tops Revenue Estimates
Syndax (SNDX) delivered earnings and revenue surprises of 5.77% and 36.69%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for Keros Therapeutics Stock Options
Investors need to pay close attention to KROS stock based on the movements in the options market lately.
Deal Dispatch: Harley-Davidson To Wipe Out? Plus, Prada's Versace Purchase Garners A Fashionable Price - Capri Holdings ( NYSE:CPRI ) , NIOX Group ( OTC:CSSPF )
Impresoft, Keros Therapeutics and Rivalry Corp. are all in the midst of exploring strategic alternatives, including sale processes. Lucid Group continues its slow climb as a Tesla rival by striking a deal to acquire now-bankrupt Nikola Corp.
KROS Initiates Exploring Strategic Alternatives, Stock Gains 18.5%
The stock rallies 18.5% after Keros initiates a strategic review process exploring alternatives, including a potential sale of the business.
Keros Therapeutics Goes Up For Sale On Heels Of Stockholder Rights Plan - Keros Therapeutics ( NASDAQ:KROS )
Keros began a formal review of strategic alternatives to enhance shareholder value. A rights plan was adopted after an investor gained an 11.2% stake in Keros. Pelosi's latest AI pick skyrocketed 169% in just one month. Click here to discover the next stock our government trade tracker is ...
Crude Oil Falls Over 4%; Keros Therapeutics Shares Jump - CarMax ( NYSE:KMX ) , Keros Therapeutics ( NASDAQ:KROS )
U.S. stocks traded lower midway through trading, with the Dow Jones index dipping more than 4% on Thursday. The Dow traded down 4.18% to 38,910.71 while the NASDAQ dipped 5.64% to 16,159.08. The S&P 500 also fell, dropping, 4.90% to 5,189.26. Consumer staples shares surged by 0.9% on Thursday.
PriceSmart Posts Better-Than-Expected Earnings, Joins Enact Holdings, DexCom And Other Big Stocks Moving Higher On Thursday - Enact Holdings ( NASDAQ:ACT ) , DexCom ( NASDAQ:DXCM )
U.S. stocks were lower, with the Dow Jones index dipping over 800 points on Thursday. Shares of PriceSmart, Inc. PSMT rose sharply during Thursday's session following better-than-expected second-quarter earnings.
Keros Therapeutics Announces Review of Strategic Alternatives
LEXINGTON, Mass., April 10, 2025 ( GLOBE NEWSWIRE ) -- Keros Therapeutics, Inc. ( "Keros" or the "Company" ) ( Nasdaq: KROS ) , a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked ...
Wall Street Analysts Think Keros Therapeutics ( KROS ) Could Surge 156.99%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 157% in Keros Therapeutics (KROS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Believe Keros Therapeutics ( KROS ) Could Rally 153.67%: Here's is How to Trade
The mean of analysts' price targets for Keros Therapeutics (KROS) points to a 153.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences - Keros Therapeutics ( NASDAQ:KROS )
LEXINGTON, Mass., Feb. 28, 2025 ( GLOBE NEWSWIRE ) -- Keros Therapeutics, Inc. ( "Keros" ) KROS, a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of ...
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
LEXINGTON, Mass., Feb. 28, 2025 ( GLOBE NEWSWIRE ) -- Keros Therapeutics, Inc. ( "Keros" ) ( Nasdaq: KROS ) , a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional ...
Keros Therapeutics, Inc. ( KROS ) Reports Q4 Loss, Misses Revenue Estimates
Keros Therapeutics (KROS) delivered earnings and revenue surprises of -22.58% and 97.11%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Keros Therapeutics Stock Plunges 81% in 3 Months: Here's Why
KROS stock crashes 81% in three months after dosing with cibotercept was halted in a phase II lung disease study due to adverse pericardial effusion events.
Keros Therapeutics ( KROS ) Soars 5.1%: Is Further Upside Left in the Stock?
Keros Therapeutics (KROS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Down -36.23% in 4 Weeks, Here's Why Keros Therapeutics ( KROS ) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Keros Therapeutics (KROS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend ...
Here's Why Keros Therapeutics ( KROS ) is Poised for a Turnaround After Losing -39.17% in 4 Weeks
Keros Therapeutics (KROS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the ...
Crude Oil Rises Sharply; JPMorgan Chase Earnings Top Views - Anitra ( AMEX:AZTR ) , Aclarion ( NASDAQ:ACON )
U.S. stocks traded higher toward the end of trading, with the S&P 500 gaining over 100 points on Wednesday. The Dow traded up 1.69% to 43,237.93 while the NASDAQ rose 2.35% to 19,491.49. The S&P 500 also rose, gaining, 1.80% to 5,947.81. Communication services shares surged by 2.4% on Tuesday.
Nasdaq Surges Over 2%; Goldman Sachs Posts Upbeat Q4 Results - Anitra ( AMEX:AZTR ) , Aclarion ( NASDAQ:ACON )
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 2% on Wednesday. The Dow traded up 1.68% to 43,232.26 while the NASDAQ rose 2.34% to 19,489.33. The S&P 500 also rose, gaining, 1.77% to 5,946.09. Consumer discretionary shares surged by 2.6% on Tuesday.
Keros Therapeutics Announces Additional Update on the Phase 2 TROPOS Trial - Keros Therapeutics ( NASDAQ:KROS )
LEXINGTON, Mass., Jan. 15, 2025 ( GLOBE NEWSWIRE ) -- Keros Therapeutics, Inc. ( "Keros" or the "Company" ) KROS, a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to ...
Keros Therapeutics Announces Additional Update on the Phase 2 TROPOS Trial
LEXINGTON, Mass., Jan. 15, 2025 ( GLOBE NEWSWIRE ) -- Keros Therapeutics, Inc. ( "Keros" or the "Company" ) ( Nasdaq: KROS ) , a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked ...
Dow Tumbles 200 Points; Liquidity Services Shares Spike Higher - Ciena ( NYSE:CIEN ) , 3D Sys ( NYSE:DDD )
U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling around 200 points on Thursday. The Dow traded down 0.46% to 43,947.18 while the NASDAQ fell 0.38% to 19,957.81. The S&P 500 also fell, dropping, 0.34% to 6,063.38. Consumer staples shares jumped by 0.5% on ...
Gold Falls Sharply; Adobe Shares Dip After Weak Revenue Outlook - 3D Sys ( NYSE:DDD ) , Adobe ( NASDAQ:ADBE )
U.S. stocks traded lower midway through trading, with the Dow Jones index falling by 0.2% on Thursday. The Dow traded down 0.18% to 44,067.70 while the NASDAQ fell 0.33% to 19,969.33. The S&P 500 also fell, dropping, 0.24% to 6,069.33. Real estate shares jumped by 0.7% on Thursday.
Nasdaq Down 50 Points; US Initial Jobless Claims Rise - Canoo ( NASDAQ:GOEV ) , Keros Therapeutics ( NASDAQ:KROS )
U.S. stocks traded mostly lower this morning, with the Nasdaq Composite falling more than 50 points on Thursday. Following the market opening Thursday, the Dow traded down 0.01% to 44,142.13 while the NASDAQ fell 0.27% to 19,979.88. The S&P 500 also fell, dropping, 0.14% to 6,075.73.
Keros Therapeutics Loses 75% Value In A Single Session - Here's Why - Keros Therapeutics ( NASDAQ:KROS )
On Thursday, Keros Therapeutics, Inc. KROS voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS trial Phase 2 trial of cibotercept ( KER-012 ) in combination with background therapy in pulmonary arterial hypertension patients.
Adobe, Keros Therapeutics, Lovesac And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Adobe ( NASDAQ:ADBE ) , ADS-TEC Energy ( NASDAQ:ADSE )
U.S. stock futures were lower this morning, with the Nasdaq futures falling around 50 points on Thursday. Shares of Adobe Inc. ADBE fell sharply in today's pre-market trading following the release of quarterly results. Adobe posted better-than-expected earnings and sales results for its fourth ...
Keros Therapeutics Announces Update on the Phase 2 TROPOS Trial
LEXINGTON, Mass., Dec. 12, 2024 ( GLOBE NEWSWIRE ) -- Keros Therapeutics, Inc. ( "Keros" or the "Company" ) ( Nasdaq: KROS ) , a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked ...
Keros Therapeutics Presents Clinical Data from its Elritercept Program at the 66th American Society of Hematology Annual Meeting and Exposition - Keros Therapeutics ( NASDAQ:KROS )
Elritercept demonstrated a durable transfusion independence in lower-risk myelodysplastic syndromes, including in patients with high transfusion burden, with a median duration of response of 134.1 weeks
Keros Therapeutics Presents Clinical Data from its Elritercept Program at the 66th American Society of Hematology Annual Meeting and Exposition
LEXINGTON, Mass., Dec. 09, 2024 ( GLOBE NEWSWIRE ) -- Keros Therapeutics, Inc. ( "Keros" or the "Company" ) ( Nasdaq: KROS ) , a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked ...
